HOOKIPA to Present Data Demonstrating the Potential of its TheraT® Technology at the Upcoming CICON Conference in Paris
19 September 2019 - 10:55PM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapeutics targeting infectious diseases and
cancers based on its proprietary arenavirus platforms, will present
the anti-cancer impact of its TheraT® technology in four poster
presentations at the CICON Cancer Immunotherapy Conference taking
place September 25-28 in Paris.
HOOKIPA’s cancer immunotherapies are based on the flexible
TheraT® technology, which is a novel, replication-attenuated,
arenavirus vector platform. TheraT® is notable for targeting
dendritic cells and inducing powerful cytotoxic T lymphocyte (CTL)
responses. TheraT® immunotherapies have been shown to control
tumors in preclinical models when targeted against various types of
tumor associated/specific antigens (viral, self-, and neo-antigens)
and can be delivered intratumorally or systemically.
The CICON posters highlight the robust preclinical data package
and broad therapeutic utility for TheraT® immunotherapies:
- Viral antigens: TheraT® directed against Human Papilloma Virus
type 16 (HPV16) antigens was immunogenic, safe, and effective in
clearing tumors and providing long-term protection in mouse models.
Combination with checkpoint inhibitors potentiated TheraT®’s
efficacy.
- Tumor-associated self-antigens (TAAs): TheraT® was employed
with two different arena viruses, in a so-called heterologous
prime-boost approach, designed to drive even greater CTL response
and thereby break tolerance. Intravenous administration of TheraT®
triggered up to 50% TAA epitope specific CTLs and established
tumors were eliminated.
- Melanoma TAA: A single dose of TheraT® was shown to reprogram
the tumor microenvironment and resulted in tumor eradication.
Based on the promising preclinical data generated to date,
HOOKIPA is planning to launch the first clinical trial of a TheraT®
immunotherapy in HPV16+ cancers in 2019.
“We believe HOOKIPA’s approach can supercharge the natural
defense mechanisms by inducing strong T cell responses and by
modulating the tumor microenvironment. With the upcoming initiation
of our first clinical program in oncology, we are excited to see
these impressive preclinical data translate to cancer patients,”
stated Joern Aldag, HOOKIPA’s Chief Executive Officer.
Additional information about HOOKIPA’s poster presentations at
CICON 2019: |
|
• |
Title: TheraT®-E7E6, a live-attenuated lymphocytic
choriomeningitis virus (LCMV)-based vector for active immunotherapy
of HPV16+ cancer |
|
|
Poster Presentation: Session A;
Thursday, September 26, 1:00-3:00pm/6:00-8:00pm; Viollet le Duc and
Mansart (Level -1) |
|
|
|
|
• |
Title: Highly efficient tumor control in a
preclinical model for HPV16+ cancer induced by a heterologous
prime/boost approach with LCMV- and Pichinde Virus (PICV)-based
TheraT® vectors |
|
|
Poster Presentation: Session B
Friday, September 27, 1:00-3:00pm/6:00-8:00pm; Viollet le Duc and
Mansart (Level -1) |
|
|
|
|
• |
Title: Arenavirus-based vector platform for
massive tumor self-antigen-specific CD8 T cell immunity |
|
|
Poster Presentation: Session A;
Thursday, September 26, 1:00-3:00pm/6:00-8:00pm; Viollet le Duc and
Mansart (Level -1) |
|
|
|
|
• |
Title: Reprogrammed tumor microenvironment by
intratumoral LCMV vector therapy promotes T cell-dependent melanoma
eradication |
|
|
Poster Presentation: Session B
Friday, September 27, 1:00-3:00pm/6:00-8:00pm; Viollet le Duc and
Mansart (Level -1) |
About HOOKIPAHOOKIPA Pharma
Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company
developing a new class of immunotherapeutics, targeting infectious
diseases and cancers based on its proprietary arenavirus platform
that is designed to reprogram the body’s immune system.
HOOKIPA’s proprietary arenavirus-based
technologies, VaxWave®*, a replication-deficient viral vector, and
TheraT®*, a replication-attenuated viral vector, are designed to
induce robust antigen specific CD8+ T cells and
pathogen-neutralizing antibodies. Both technologies are designed to
allow for repeat administration while maintaining an immune
response. TheraT® has the potential to induce CD8+ T cell response
levels previously not achieved by other published immunotherapy
approaches. HOOKIPA’s “off-the-shelf” viral vectors target
dendritic cells in vivo to activate the immune system.
HOOKIPA’s VaxWave®-based prophylactic
cytomegalovirus vaccine candidate is currently in a Phase 2
clinical trial in patients awaiting kidney transplantation from
living cytomegalovirus-positive donors. To expand its infectious
disease portfolio, HOOKIPA has entered into a collaboration and
licensing agreement with Gilead Sciences, Inc. to jointly research
and develop functional cures for HIV and Hepatitis B infections.
HOOKIPA is building a proprietary immuno-oncology pipeline by
targeting virally mediated cancer antigens, self-antigens and
next-generation antigens.
TheraT® and VaxWave® are not approved anywhere
globally and their safety and efficacy have not been
established.
Find out more about HOOKIPA online at
www.hookipapharma.com.
*Registered in Europe; Pending in the US.
HOOKIPA Forward Looking
StatementsCertain statements set forth in this press
release constitute “forward-looking” statements within the meaning
of the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements can be identified by terms such
as “believes,” “expects,” “plans,” “potential,” “would” or similar
expressions and the negative of those terms. Such forward-looking
statements involve substantial risks and uncertainties that could
cause HOOKIPA’s research and clinical development programs, future
results, performance or achievements to differ significantly from
those expressed or implied by the forward-looking statements. Such
risks and uncertainties include, among others, the uncertainties
inherent in the drug development process, including HOOKIPA’s
programs’ early stage of development, the process of designing and
conducting preclinical and clinical trials, the regulatory approval
processes, the timing of regulatory filings, the challenges
associated with manufacturing drug products, HOOKIPA’s ability to
successfully establish, protect and defend its intellectual
property and other matters that could affect the sufficiency of
existing cash to fund operations and HOOKIPA’s ability to achieve
the milestones under the agreement with Gilead. HOOKIPA undertakes
no obligation to update or revise any forward-looking statements.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to the
business of the company in general, see HOOKIPA’s quarterly report
on Form 10-Q for the quarter ended June 30, 2019 which is available
on the Security and Exchange Commission’s website at www.sec.gov
and HOOKIPA’s website at www.hookipapharma.com.
For further information, please contact: |
|
|
|
Media |
|
Investors |
Nina Waibel |
|
Matt Beck |
Senior Director - Communications |
|
Executive Director – Investor Relations |
Nina.Waibel@HookipaPharma.com |
|
Matthew.Beck@HookipaPharma.com |
|
|
|
Media enquiries |
|
|
Sue Charles/ Ashley Tapp |
|
|
Instinctif Partners |
|
|
Hookipa@Instinctif.com |
|
|
+44 (0)20 7457 2020 |
|
|
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Apr 2024 to May 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From May 2023 to May 2024